1978 related articles for article (PubMed ID: 7847516)
1. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
3. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses.
Antoniou G; Kalogirou D; Karakitsos P; Antoniou D; Kalogirou O; Giannikos L
Maturitas; 1997 Mar; 26(2):103-11. PubMed ID: 9089559
[TBL] [Abstract][Full Text] [Related]
4. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
[TBL] [Abstract][Full Text] [Related]
5. Hormonal intrauterine devices.
Rybo G; Andersson K; Odlind V
Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
[TBL] [Abstract][Full Text] [Related]
6. Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device.
Raudaskoski TH; Tomás EI; Paakkari IA; Kauppila AJ; Laatikainen TJ
Maturitas; 1995 Jun; 22(1):47-53. PubMed ID: 7666816
[TBL] [Abstract][Full Text] [Related]
7. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol.
Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A
Arch Gynecol Obstet; 1998; 261(4):201-8. PubMed ID: 9789651
[TBL] [Abstract][Full Text] [Related]
8. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
[TBL] [Abstract][Full Text] [Related]
9. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response.
Raudaskoski T; Tapanainen J; Tomás E; Luotola H; Pekonen F; Ronni-Sivula H; Timonen H; Riphagen F; Laatikainen T
BJOG; 2002 Feb; 109(2):136-44. PubMed ID: 11888095
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy.
Suvanto-Luukkonen E; Sundström H; Penttinen J; Läärä E; Pramila S; Kauppila A
Maturitas; 1997 Apr; 26(3):211-7. PubMed ID: 9147353
[TBL] [Abstract][Full Text] [Related]
11. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
Boonkasemsanti W; Reinprayoon D; Pruksananonda K; Niruttisard S; Triratanachat S; Leepipatpaiboon S; Wannakrairot P
Hum Reprod; 1996 Oct; 11 Suppl 2():115-23. PubMed ID: 8982753
[TBL] [Abstract][Full Text] [Related]
12. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy.
Varila E; Wahlström T; Rauramo I
Fertil Steril; 2001 Nov; 76(5):969-73. PubMed ID: 11704119
[TBL] [Abstract][Full Text] [Related]
13. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy.
Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A; Rutanen EM
Maturitas; 1995 Nov; 22(3):255-62. PubMed ID: 8746884
[TBL] [Abstract][Full Text] [Related]
15. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy.
Suhonen SP; Holmström T; Allonen HO; Lähteenmäki P
Fertil Steril; 1995 Feb; 63(2):336-42. PubMed ID: 7843440
[TBL] [Abstract][Full Text] [Related]
16. Endometrial lymphomyeloid cells in abnormal uterine bleeding due to levonorgestrel (Norplant).
Clark DA; Wang S; Rogers P; Vince G; Affandi B
Hum Reprod; 1996 Jul; 11(7):1438-44. PubMed ID: 8671483
[TBL] [Abstract][Full Text] [Related]
17. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
[TBL] [Abstract][Full Text] [Related]
18. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
19. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
Luukkainen T; Toivonen J
Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
[TBL] [Abstract][Full Text] [Related]
20. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience.
Suvanto-Luukkonen E; Kauppila A
Fertil Steril; 1999 Jul; 72(1):161-3. PubMed ID: 10428167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
